GLP-1R agonists for the treatment of obesity: a patent review (2015-present)
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Glucagon-like peptide-1 (GLP-1) is an endogenous peptide which is secreted by enteroendocrine L cells, GLP-1 receptor agonists (GLP-1 RAs) can exhibit glucoregulation by stimulating insulin release, promote satiety, delay gastric emptying, and reduce energy intake. Liraglutide is the only GLP-1 RA approved for the treatment of obesity. The phase III clinical study of semaglutide has completed and the result showed significant weight loss effect. GLP-1 RAs have been proven to be safe and effective in clinical trials, they are considered to be promising anti-obesity drugs. AREAS COVERED: This review provides an overview of recently published patents describing modified GLP-1 RAs, multi-agonists in the treatment or prevention of obesity from January 2015 to April 2020. Moreover, small molecule GLP-1 RAs, recombinant fusion proteins, combination of GLP-1 RAs with other drugs and the preparation of GLP-1 RAs are also covered. EXPERT OPINION: Currently, research on anti-obesity effect of modified GLP-1 RAs has grown significantly, liraglutide accounts for approximately 56% of the global obesity drug market. Long-acting analogues and multifunctional peptides showed good weight loss activity. As more and more clinical trials are carried out, we believe that GLP-1 RAs will occupy an important position in the market of obesity treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“The wide-spread distribution of GLP-1 R expression within the CNS as well as the autonomic and enteric nervous systems has spurred investigation into how physiological gut-derived GLP-1, as well as pharmacological activation of the GLP-1 R, controls appetite and body weight [6].”
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282 · cited 1×
“…oral preparation of GLP-1 receptor agonists semaglutide was approved in 2019, patents relate to the oral preparation or the controlled-release system have been increasingly applied, and the development of oral peptide preparation will increase in the future. resisting protease degradation [21].”
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · cited 1×
“Administration of FGF21 compounds can decrease the body weight, blood glucose and plasma lipids as well as improve insulin sensitivity [142,143].”
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1
Johnen, H., Lin, S., Kuffner, T., Brown, D. A., Tsai, V. W.-W., Bauskin, A. R., Wu, L., Pankhurst, G., Jiang, L., Junankar, S., et al. (2007) · Nature Medicine · doi:10.1038/nm1677 · Cited by 612 · cited 1×
“Accumulating evidences support the therapeutic utility of MIC-1 in metabolic disorders such as obesity [138].”
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347
Macia, L., Tsai, V. W.-W., Nguyen, A. D., Johnen, H., Kuffner, T., Shi, Y.-C., Lin, S., Herzog, H., Brown, D. A., Breit, S. N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034868 · Cited by 211 · cited 1×
“Transgenic mice overexpress MIC-1 gain less weight and body fat both on a normal low-fat diet and on a high-fat diet [139].”
Cited by
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Zhou, Y., Chen, M., Liu, L., & Chen, Z. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s348025 · Cited by 46
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Development strategies for GLP-1R ligands [16,52,53].”
Wu, T., Zhang, Y., Shi, Y., Yu, K., Zhao, M., Liu, S., & Zhao, Z. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01202-1 · Cited by 38
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Metadata
- Authors
- Liu, C., Zou, Y., & Qian, H.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2020-09-11
- Volume
- 30
- Issue
- 10
- Pages
- 781-794
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W3068552074
- Cited by
- 28
- References
- 13
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1R agonists for the treatment of obesity: a patent review (2015-present). https://app.cochat.ai/papers/10.1080/13543776.2020.1811851
- The paper
- Liu, C., Zou, Y., & Qian, H. (2020). GLP-1R agonists for the treatment of obesity: a patent review (2015-present). Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2020.1811851
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.